Darmstadt, Germany

Simon Lawrence Goodman

This inventor holds 27 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Integrin Inhibitors. Top assignees: Merck Patent Gmbh, Merck Patent Gesellschaft MIT Beschrankter Haftung, Merck Patent Gesellschaft MIT. Active years: 1997-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Simon Lawrence Goodman. Retrieved from https://idiyas.com/inventor/simon-lawrence-goodman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 

% Patents Active = 40.7

 

 

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 187(Granted Patents)


Location History:

  • Darmstadt, DE (1997 - 2011)
  • Griesheim, GB (2013)
  • Griesheim, DE (2003 - 2019)

Company Filing History:


Years Active: 1997-2019

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Integrin Inhibitors
Pharmaceutical Composition
Anti-Alpha V-Integrin
Hybrid Antibodies
Cyclic Peptides
Oligopeptides
Tumor Treatment
Acetyltransferase Gene
Isoquinoline Derivatives
Angiogenesis Inhibitor
Bicyclic Amino Acids
Dibenzoazulene Derivatives
27 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Simon Lawrence Goodman

Introduction

Simon Lawrence Goodman is a prolific inventor based in Darmstadt, Germany, with an impressive portfolio of 27 patents. His work primarily focuses on pharmaceutical compositions and diagnostics, demonstrating a strong commitment to advancing medical science and technology. Goodman's contributions have led to significant advancements in the treatment of disorders and the detection of integrin complexes.

Latest Patents

Among his latest patents, one highlights a **method of treating disorders using a pharmaceutical composition of oligopeptides**. This invention describes a pharmaceutical composition that incorporates cyclic oligopeptides, along with lipophilic and amphiphilic compounds, which can be utilized in various environments, either in the presence or absence of water. This innovative approach opens new avenues for creating effective pharmaceutical formulations.

Another noteworthy patent is related to **antibodies for the detection of integrin complexes in FFPE material**. This invention introduces antibodies that bind the extracellular domain of integrins, facilitating their detection in archival formalin-fixed paraffin-embedded tissue. The patent also outlines methods for preparing monoclonal rabbit antibodies and screening anti-integrin antibodies, which are particularly useful in immunohistochemistry applications.

Career Highlights

Simon Lawrence Goodman has worked with notable organizations such as Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung, where he has contributed his expertise in patent law and innovation. His experience in these companies showcases his strong background in both scientific research and the business aspects of inventions.

Collaborations

Throughout his career, Goodman has collaborated with esteemed colleagues, including Alfred Jonczyk and Horst Kessler. These partnerships have likely enhanced his research capabilities and contributed to the depth of innovations resulting from his initiatives.

Conclusion

Simon Lawrence Goodman's contributions to the field of pharmaceuticals and diagnostics reflect a dedicated inventor striving to push the boundaries of medical advancements. With 27 patents to his name and a focus on oligopeptides and integrin detection, Goodman continues to leave an indelible mark on the world of innovation. His work not only exemplifies the essence of scientific exploration but also highlights the intricate connection between research and practical applications in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…